Comparative Pharmacology
Head-to-head clinical analysis: ALPROSTADIL versus LATISSE.
Peer-Reviewed Evidence
Head-to-head clinical analysis: ALPROSTADIL versus LATISSE.
ALPROSTADIL vs LATISSE
Comparing the clinical profiles, pharmacokinetic behaviors, and safety indices of these two therapeutic agents.
Alprostadil is a synthetic prostaglandin E1 (PGE1) that causes vasodilation by binding to prostanoid EP receptors, increasing intracellular cAMP, and relaxing smooth muscle. It also inhibits platelet aggregation.
Bimatoprost is a synthetic prostamide analog that selectively mimics the effects of prostamide F2α. It increases the growth of eyelashes by prolonging the anagen (growth) phase and increasing the number of hairs. The exact molecular mechanism is thought to involve binding to prostamide receptors, leading to modulation of intracellular signaling pathways that regulate hair follicle cycling.
Initial: 20-40 mcg IV bolus over 1-2 seconds; then 30-70 mcg/min continuous IV infusion for erectile dysfunction via intracavernosal injection: 2.5-10 mcg; for patent ductus arteriosus: 0.05-0.1 mcg/kg/min continuous IV infusion.
One drop applied to the upper eyelid margin at the base of the eyelashes once daily using the provided sterile applicators.
None Documented
None Documented
Clinical Note
moderateAlprostadil + Limaprost
"Alprostadil may increase the antiplatelet activities of Limaprost."
Clinical Note
moderateAlprostadil + Epoprostenol
"Alprostadil may increase the antiplatelet activities of Epoprostenol."
Clinical Note
moderateTiaprofenic acid + Alprostadil
"The therapeutic efficacy of Alprostadil can be decreased when used in combination with Tiaprofenic acid."
Clinical Note
moderateCarprofen + Alprostadil
5-10 minutes; rapidly metabolized in the lungs, clinical effect lasts longer due to continuous infusion.
The terminal elimination half-life of bimatoprost in plasma is approximately 45 minutes (range 30-60 minutes) after topical ocular application in humans. This short half-life reflects rapid systemic clearance, but the drug's ocular hypotensive effect persists for 24 hours due to tissue binding.
Primarily via urine (90%) as metabolites; 10% unchanged; minimal fecal excretion.
Primarily renal elimination of metabolites; less than 5% of unchanged bimatoprost is excreted in urine. Fecal excretion accounts for approximately 25% of the dose, predominantly as metabolites. Biliary excretion is minimal.
Category C
Category C
Prostaglandin Analog
Prostaglandin Analog
"The therapeutic efficacy of Alprostadil can be decreased when used in combination with Carprofen."